Precision’s Gerry Messerschmidt Talks Immunotherapy with ASCO Post
There is emerging interest in developing immunologic therapies in cancer. However, the cellular interactions in the immune system are complex, involving many cell types and various chemical mediators. To shed some light on this emerging field, The ASCO Post recently spoke with Gerald L. Messerschmidt, MD, FACP, Chief Medical Officer of Precision.